Results 221 to 230 of about 127,286 (242)

VAS value set still has its own application value compare with TTO value set of EQ-5D-3L in Chinese population. [PDF]

BMC Med Res Methodol
Zhuo L, Gao S, Jin R, Zhuo L, Wang X.
europepmc   +1 more source

Sclerophyllous structural and chemical traits of mite‐induced galls on Crinodendron patagua (Elaeocarpaceae) leaves

Plant Biology, Volume 28, Issue 6, Page 2039-2053, October 2026.
Eriophyid mites reprogram the structural and biochemical traits of sclerophyllous leaves in Crinodendron patagua, promoting the formation of nutrient‐rich and protective gall tissues. Abstract Sclerophyllous plants present a suite of traits, including small, leathery leaves with thick cuticles, dense trichomes and sclerified tissues, which are often ...
L. M. Guedes, L. Rodríguez‐Cerda, N. Aguilera, E. Grandón, F. R. Valeriano, J. F. de Lima, J. F. P. de Oliveira, B. G. Ferreira   +7 more
wiley   +1 more source

Predicting Danish EQ-5D-5L Utilities Based on United Kingdom EQ-5D-3L Utilities for Use in Health Economic Models. [PDF]

Pharmacoecon Open
Torkilseng EB, Clarke N, Sopina L, Oddershede L, Wolf RT, Lawrance R, Trigg A, Bennett B, Shaw JW.   +8 more
europepmc   +1 more source

Health-Related Quality of Life in Patients with Friedreich Ataxia Using Mobility Assistive Technologies: Limited Fit of the EQ-5D-3L Mobility Dimension. [PDF]

Neurol Ther
Buchholz M, Pfaff M, Iskandar A, Reetz K, Schulz JB, Grobe-Einsler M, Klockgether T, Michalowsky B, EFACTS Study Group.   +8 more
europepmc   +1 more source

Psychometric Assessment of the EQ-5D-3L And ReQoL Measures in Secure Care Patients with an Intellectual Disability: Reliability, Agreement, Construct Validity, and Responsiveness

Franklin M, Condie J, Doorn KA, Foscarini-Craggs P, Harrison TL, Iranpour A, McKinnon I, McNamara R, Randell E, Riaz M, Rose S, Zubala A, Hackett S.   +12 more
europepmc   +1 more source

How to interpret patient-reported outcomes? - Stratified adjusted minimal important changes for the EQ-5D-3L in hip and knee replacement patients. [PDF]

J Patient Rep Outcomes
Salvi I, Ehlig D, Vogel J, Bischof A, Geissler A.   +4 more
europepmc   +1 more source

Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation. [PDF]

Eur J Health Econ
Mukuria C, Franklin M, Hinde S.
europepmc   +1 more source

Quality of life of patients with cutaneous leishmaniasis: A comparative analysis of the EQ-5D-3L and CLIQ questionnaires. [PDF]

PLoS One
Galvão EL, de Pina Carvalho J, Machado de Assis TS, Freire ML, Cota G, Nascimento Silva S.   +5 more
europepmc   +1 more source

Population-level norm values by EQ-5D-3L in Hungary - a comparison of survey results from 2022 with those from 2000. [PDF]

Qual Life Res
Inotai A, Nagy D, Kaló Z, Vokó Z.
europepmc   +1 more source

Measurement properties of the EQ-5D-3L, EQ-5D-5L, and SF-6Dv2 in patients with late-onset Pompe disease. [PDF]

Eur J Health Econ
Xu RH, Luo N, Dong D.
europepmc   +1 more source